DPP-IV Inhibitors: A Global Strategic Business Report
San Jose, California (PRWEB) October 07, 2011
Follow us on LinkedIn - Type–2 diabetes is becoming a global epidemic, with the incidence and prevalence of the condition as well as related risk factors, such as obesity, continuously rising worldwide. The condition creates a substantial burden on the healthcare system globally. Insulin and several other therapies for treating the condition have been available for several years. However, most of the presently available therapies largely focus on glycaemic control, with lesser potential to offer respite from other factors. Besides, certain patients continue to confront with issues, such as adherence to treatment regimen due to side effects including hypoglycemia and weight gain, and secondary failures. In the recent years, diabetic patients have seen a new ray of hope in the form of new drug classes, such as DPP-4 Inhibitors. Patients are increasingly gaining access to new drugs that offer novel benefits, such as minimized cardiovascular risk factors in addition to offering glycaemic control. Inhibitors of DPP-4 act on GLP-1 and GIP, the two targets for reducing blood glucose level.
DPP-4 inhibitors, also known as gliptins, the latest addition to the repertoire of anti-diabetic medications, made its way to the market in the year 2006, following the launch of the first drug in the class- Januvia, in the US. Excellent safety profile of the drug, in addition to the convenience of being an oral drug with once-daily dosage, has led to tremendous success of the drug since its launch. Several other drugs with comparable action mechanism have already made their way into the market in the subsequent years, and many are currently in various stages of development. DPP-4 inhibitors are expected to emerge as the largest drug class in the oral anti-diabetics in the following years. This ascend of the DPP-IV inhibitor drug class would be supported by increasing acceptance of drugs in this class, as well as the loss of patent protection for certain leading drugs in other anti-diabetic drug classes.
DPP-IV inhibitors are expected to witness significant success, mainly as add-on therapies to metformin. However, these drugs do have the potential to replace metformin as a stand-alone therapy, which is mainly due to inherent advantages, such as significantly lower levels of hypoglycemia, easily manageable gastro-intestinal side effects, and the absence of need for dose titration as required in metformin. Besides, the lower side-effect profile of the DPP-IV inhibitor drugs is expected to make them more popular, ahead of TZDs and SUs as add-on therapies.
The US represents the largest regional market for DPP-IV Inhibitors worldwide, as stated by the new market research report on DPP-IV Inhibitors. Europe trails behind the US market. However, growth in the market would be led by Asia-Pacific, which is projected to be the fastest growing regional market during the analysis period.
Despite significant interest in this class, drugs representing the DPP-IV drug class are largely considered similar in terms of efficacy. Although there is a lack of significant data comparing the existing drugs, currently available drugs fail to show any huge differences in terms of clinical efficacy in terms of glycaemic control. Resultantly, patients and physicians, along with payers, found little incentive for moving away from established drugs such as Januvia to new drugs launched in the class. Consequently, Januvia and its combination therapy, Janumet, are expected to witness continued growth in the following years, with other drugs achieving relatively lesser success. Most other drugs that have been launched in the recent years in the DPP-4 drug class, and a few in the pipeline are seen as met-too products, and are not expected to find significant difficulty in capturing into Januvia’s share in the following years. Moreover, despite being well tolerated and having an excellent safety profile, most DPP-4 inhibitors are yet to be established with respect to the durability of their effects. As a result, outcomes of long-term studies become vital for continued growth of these medications.
Major players profiled in the report include Arisaph Pharmaceuticals Inc., AstraZeneca Plc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Takeda Pharmaceutical Company Limited, among others.
The research report titled “DPP-IV Inhibitors: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the DPP-IV inhibitors markets, current market trends, key growth drivers, overview of major drugs, annual sales of key drugs, drug pipeline analysis, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for DPP-IV inhibitors market for the years 2008 through 2017 for the following geographic markets - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. The report also analyzes the global DPP-IV market by the following drug compounds – Sitagliptin, Vildagliptin, Saxagliptin, and others.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/DPP_IV_Inhibitors_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/